New vs existing treatment for diabetic macular edema
Treatments studied
Part of Eyes & vision clinical trials.
This study compares a new medication, tabirafusp tedromer, to an existing treatment, aflibercept, for people with diabetic macular edema (swelling in the back of the eye from diabetes). It may help if your DME hasn't improved or you're looking for a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have diabetic macular edema (DME) in the study eye, whether or not you've been treated before.
- You must be 18 years or older and have Type 1 or Type 2 diabetes.
- Your average blood sugar level (hemoglobin A1C) must be 12% or less.
- You cannot have active new blood vessels in the colored part of your eye (iris) or the drainage angle, or glaucoma from such vessels.
- You cannot have a current or past detached retina (retina pulling away from the back of the eye).
- You must be able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This study tests a treatment for diabetic macular edema (swelling in the back of the eye caused by diabetes) in people who have not had eye injections before. It aims to see if the treatment can improve vision.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial tests whether combining a steroid implant (dexamethasone) with an anti-VEGF injection (aflibercept) works better than the injection alone for people with diabetic macular edema who haven't been treated yet. It aims to improve vision and reduce retinal swelling.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.